Roche eyes October decision by FDA for wet AMD implant

The FDA has started a review of a new implant version of Roche's ranibizumab therapy for wet age-related macular degeneration, that could offer patients with the sight-robbing disorder an a

Novartis’ blockbuster hope Beovu clears EMA advisory panel

Iveric rockets on mid-stage trial of Zimura in dry AMD

Novartis backs brolucizumab with new head-to-head Eylea tria...

Regeneron to develop long release Eylea successor

Regeneron teams with Ocular Therapeutix to develop next-gen Eylea formulation